New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.62 0.56 +1.22%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Where the cash went Twelve months to Sep 30, 2026

Free cash flow was $23.8B, and none of it went on dividends or buybacks. Cash rose by $6.7B. Lines the picture does not name came to −$17.1B. What is a cash flow statement?

Free cash flow
$23.8B 100.0% of operating cash flow
Returned to shareholders
$0.00 0.00% of free cash flow
Debt, net
$0.00 borrowed
Change in cash
+$6.7B over the period
Where the cash went, in billions of dollars
Operating cash flow23.8
Free cash flow23.8
Other−17.1
Change in cash6.7
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, three quarters
Q2 FY25Q4 FY25Q2 FY26
Operating cash flow$15.4B$26.0B$21.6B
Capex−$6.5B−$7.4B−$7.1B
Free cash flow$8.8B$18.6B$14.5B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more TTM periods

5,587.98 5,587.98 4,505.89 —
Operating Cash Flow
26,024.74 — 21,596.60 23,792.82
Investing cash flow
2,369.54 — 4,065.34 4,291.09
Financing cash flow
(20,617.45) — (18,255.43) (21,866.43)
Ending Cash
34,150.58 — 33,481.82 24,547.02

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026